Format

Send to

Choose Destination
Chin J Cancer. 2017 Mar 3;36(1):25. doi: 10.1186/s40880-017-0194-7.

Ailanthone: a new potential drug for castration-resistant prostate cancer.

Peng S1, Yi Z2, Liu M3,4.

Author information

1
East China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Rd, Shanghai, 200241, P.R. China.
2
East China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Rd, Shanghai, 200241, P.R. China. zfyi@bio.ecnu.edu.cn.
3
East China Normal University and Shanghai Fengxian District Central Hospital Joint Center for Translational Medicine, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Rd, Shanghai, 200241, P.R. China. myliu@bio.ecnu.edu.cn.
4
Department of Molecular and Cellular Medicine, Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M University Health Sciences Center, Houston, TX, 77030, USA. myliu@bio.ecnu.edu.cn.
PMID:
28257652
PMCID:
PMC5336637
DOI:
10.1186/s40880-017-0194-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center